Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Otago Medical School staff profiles

Dr Glen Reid

PositionSenior Lecturer
DepartmentDepartment of Pathology (Dunedin)
Teaching
  • Research student supervision: 15 Summer Studentships, 6 Honours students, 3 PhD candidates
  • Lecturer for PATH 302
  • Tutor for ELM2 (Pathology and Chemical Pathology)
Memberships
  • Member, International Association for the Study of Lung Cancer (IASLC), 2012-present
  • Member, International Mesothelioma Interest Group (iMig), 2011-present
  • Associate member, Maurice Wilkins Centre for Molecular Discovery (MWC) 2018–present
  • Member, New Zealand Society for Oncology (NZSO) 2018–present

Research

My research program focuses on two main areas:

  1. Translational research into the asbestos-related cancer malignant pleural mesothelioma (MPM). MPM is a rare but very aggressive cancer with one of the lowest 5-year survival rates. There are no early detection markers and few effective therapies. My work focuses on the role of microRNAs in the biology of MPM and encompasses biomarker discovery and novel therapeutic approaches. This research is a continuation of the work I led in Sydney which identified tumour and blood markers and resulted in a phase I clinical trial of microRNA replacement therapy (NCT 02369198).
  2. Understanding the phenomenon of drug tolerance in malignant melanoma and lung cancer. Many melanoma and lung cancer patients frequently show dramatic responses when treated with targeted therapies (kinase inhibitors). Unfortunately, these responses are short-lived and patients relapse with resistant tumours. Together with Dr Cath Drummond, I am investigated the ability of cancer cells to shift to drug-tolerant states, allowing their initial survival – and eventual resistance – following treatment with targeted therapies. This work will be funded by a recently awarded Marsden project grant.

Additional details

There are several research projects available, ranging from Honours/Masters to PhD. Interested graduate and postgraduate students are encouraged to make contact to further discuss these projects.

  1. Project Title: The expression of novel tumour suppressor gene variants in malignant pleural mesothelioma biology. Level: Honours / Masters
  2. Project Title: De novo detection of tumour suppressor mutations in malignant pleural mesothelioma. Level: Honours / Masters
  3. Project Title: Drivers of tolerance to TKIs in lung cancer and melanoma. Level: PhD
  4. Project Title: Using CRISPR to tag tumour suppressor gene isoforms in malignant melanoma. Level: PhD

Publications

van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., … Reid, G. (2017). Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncology, 18(10), 1386-1396. doi: 10.1016/S1470-2045(17)30621-6

Johnson, T. G., Schelch, K., Cheng, Y. Y., Williams, M., Sarun, K. H., Kirschner, M. B., … Reid, G. (2018). Dysregulated expression of the microRNA miR-137 and its target YBX1 contribute to the invasive characteristics of malignant pleural mesothelioma. Journal of Thoracic Oncology, 13(2), 258-272. doi: 10.1016/j.jtho.2017.10.016

Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., … TCGA Research Network, including Reid, G., … Ladanyi, M. (2018). Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discovery, 8(12), 1549-1565. doi: 10.1158/2159-8290.CD-18-0804

Reid, G., Pel, M. E., Kirschner, M. B., Cheng, Y. Y., Mugridge, N., Weiss, J., … van Zandwijk, N. (2013). Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma. Annals of Oncology, 24(12), 3128-3135. doi: 10.1093/annonc/mdt412

Kirschner, M. B., Kao, S. C., Edelman, J. J., Armstrong, N. J., Vallely, M. P., van Zandwijk, N., & Reid, G. (2011). Haemolysis during sample preparation alters microRNA content of plasma. PLoS ONE, 6(9), e24145. doi: 10.1371/journal.pone.0024145

Chapter in Book - Research

Maher, S. G., Bibby, B. A. S., Moody, H. L., & Reid, G. (2015). MicroRNAs and cancer. In S. G. Gray (Ed.), Epigenetic cancer therapy. (pp. 67-90). Amsterdam, The Netherlands: Academic Press. doi: 10.1016/B978-0-12-800206-3.00004-5

^ Top of page

Journal - Research Article

Kazantseva, M., Mehta, S., Eiholzer, R. A., Gimenez, G., Bowie, S., Campbell, H., Reily-Bell, A. L., … Ray, S., Drummond, C. J., Reid, G., … Wiles, A., Morrin, H. R., Reader, K. L., Hung, N. A., Baird, M. A., Slatter, T. L., & Braithwaite, A. W. (2019). The Δ133p53β isoform promotes an immunosuppressive environment leading to aggressive prostate cancer. Cell Death & Disease, 10, 631. doi: 10.1038/s41419-019-1861-1

Johnson, T. G., Schelch, K., Cheng, Y. Y., Williams, M., Sarun, K. H., Kirschner, M. B., … Reid, G. (2018). Dysregulated expression of the microRNA miR-137 and its target YBX1 contribute to the invasive characteristics of malignant pleural mesothelioma. Journal of Thoracic Oncology, 13(2), 258-272. doi: 10.1016/j.jtho.2017.10.016

Ahmadzada, T., Reid, G., & McKenzie, D. R. (2018). Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. Biophysical Reviews, 10(1), 69-86. doi: 10.1007/s12551-017-0392-1

Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., … TCGA Research Network, including Reid, G., … Ladanyi, M. (2018). Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discovery, 8(12), 1549-1565. doi: 10.1158/2159-8290.CD-18-0804

Schelch, K., Kirschner, M. B., Williams, M., Cheng, Y. Y., van Zandwijk, N., Grusch, M., & Reid, G. (2018). A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma. Molecular Oncology, 12(1), 58-73. doi: 10.1002/1878-0261.12150

Schelch, K., Wagner, C., Hager, S., Pirker, C., Siess, K., Lang, E., … Reid, G., … Hoda, M. A. (2018). FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. Carcinogenesis, 39(4), 534-545. doi: 10.1093/carcin/bgy018

Winata, P., Williams, M., McGowan, E., Nassif, N., van Zandwijk, N., & Reid, G. (2017). The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection. BMC Research Notes, 10, 600. doi: 10.1186/s13104-017-2930-0

van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., … Reid, G. (2017). Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncology, 18(10), 1386-1396. doi: 10.1016/S1470-2045(17)30621-6

Kao, S. C., Cheng, Y. Y., Williams, M., Kirschner, M. B., Madore, J., Lum, T., … Reid, G. (2017). Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. Journal of Thoracic Oncology, 12(9), 1421-1433. doi: 10.1016/j.jtho.2017.05.024

Kao, S. C., Kirschner, M. B., Cooper, W. A., Thran, T., Burgers, S., Wright, C., … Reid, G. (2016). A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. British Journal of Cancer, 114(5), 524-531. doi: 10.1038/bjc.2015.470

Cheng, Y. Y., Wright, C. M., Kirschner, M. B., Williams, M., Sarun, K. H., Sytnyk, V., … Reid, G. (2016). KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. Molecular Cancer, 15, 44. doi: 10.1186/s12943-016-0529-z

Williams, M., Kirschner, M. B., Cheng, Y. Y., Hanh, J., Weiss, J., Mugridge, N., … Reid, G. (2015). miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget, 6(27), 23480-23495. doi: 10.18632/oncotarget.4346

Kirschner, M. B., Pulford, E., Hoda, M. A., Rozsas, A., Griggs, K., Cheng, Y. Y., … Reid, G. (2015). Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. British Journal of Cancer, 113(6), 963-969. doi: 10.1038/bjc.2015.286

Kirschner, M. B., Cheng, Y. Y., Armstrong, N. J., Lin, R. C. Y., Kao, S. C., Linton, A., … Reid, G. (2015). MiR-Score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Molecular Oncology, 9(3), 715-726. doi: 10.1016/j.molonc.2014.11.007

Linton, A., Cheng, Y. Y., Griggs, K., Kirschner, M. B., Gattani, S., Srikaran, S., … Reid, G. (2014). An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 110(2), 510-519. doi: 10.1038/bjc.2013.731

Cheng, N. C., van Zandwijk, N., & Reid, G. (2014). Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5. PLoS ONE, 9(3), e90374. doi: 10.1371/journal.pone.0090374

Kirschner, M. B., Edelman, J. J. B., Kao, S. C.-H., Vallely, M. P., van Zandwijk, N., & Reid, G. (2013). The impact of hemolysis on cell-free microRNA biomarkers. Frontiers in Genetics, 4, 94. doi: 10.3389/fgene.2013.00094

Wright, C. M., Kirschner, M. B., Cheng, Y. Y., O'Byrne, K. J., Gray, S. G., Schlech, K., … Reid, G. (2013). Long non coding RNAs (lncRNAs) are dysregulated in malignant pleural mesothelioma (MPM). PLoS ONE, 8(8), e70940. doi: 10.1371/journal.pone.0070940

Cheng, Y. Y., Kirschner, M. B., Cheng, N. C., Gattani, S., Klebe, S., Edelman, J. J. B., … Reid, G. (2013). ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma. Journal of Thoracic Oncology, 8(10), 1317-1328. doi: 10.1097/JTO.0b013e3182a0840a

Reid, G., Pel, M. E., Kirschner, M. B., Cheng, Y. Y., Mugridge, N., Weiss, J., … van Zandwijk, N. (2013). Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma. Annals of Oncology, 24(12), 3128-3135. doi: 10.1093/annonc/mdt412

Kirschner, M. B., Cheng, Y. Y., Badrian, B., Kao, S. C., Creaney, J., Edelman, J. J. B., … Reid, G. (2012). Increased circulating miR-625-3p: A potential biomarker for patients with malignant pleural mesothelioma. Journal of Thoracic Oncology, 7(7), 1184-1191. doi: 10.1097/JTO.0b013e3182572e83

Reid, G., Kirschner, M. B., & van Zandwijk, N. (2011). Circulating microRNAs: Association with disease and potential use as biomarkers. Critical Reviews in Oncology/Hematology, 80(2), 193-208. doi: 10.1016/j.critrevonc.2010.11.004

Kirschner, M. B., Kao, S. C., Edelman, J. J., Armstrong, N. J., Vallely, M. P., van Zandwijk, N., & Reid, G. (2011). Haemolysis during sample preparation alters microRNA content of plasma. PLoS ONE, 6(9), e24145. doi: 10.1371/journal.pone.0024145

^ Top of page

Journal - Research Other

Ahmadzada, T., Reid, G., & Kao, S. (2018). Biomarkers in malignant pleural mesothelioma: Current status and future directions. Journal of Thoracic Disease, 10, S1003-S1007. doi: 10.21037/jtd.2018.04.31

Williams, M., Cheng, Y. Y., Blenkiron, C., & Reid, G. (2017). Exploring mechanisms of microRNA downregulation in cancer. MicroRNA, 6(1), 2-16. doi: 10.2174/2211536605666161208154633

Robb, T., Reid, G., & Blenkiron, C. (2017). Exploiting microRNAs as cancer therapeutics. Targeted Oncology, 12(2), 163-178. doi: 10.1007/s11523-017-0476-7

Reid, G., Kao, S. C., Pavlakis, N., Brahmbhatt, H., MacDiarmid, J., Clarke, S., … van Zandwijk, N. (2016). Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer [Special report]. Epigenomics, 8(8), 1079-1085. doi: 10.2217/epi-2016-0035

Kao, S. C., Fulham, M., Wong, K., Cooper, W., Brahmbhatt, H., MacDiarmid, J., … Reid, G., & van Zandwijk, N. (2015). A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. American Journal of Respiratory & Critical Care Medicine, 191(12), 1467-1469. doi: 10.1164/rccm.201503-0461LE

Reid, G. (2015). MicroRNAs in mesothelioma: From tumour suppressors and biomarkers to therapeutic targets. Journal of Thoracic Disease, 7(6), 1031-1040. doi: 10.3978/j.issn.2072-1439.2015.04.56

Kirschner, M. B., van Zandwijk, N., & Reid, G. (2013). Cell-free microRNAs: Potential biomarkers in need of standardized reporting. Frontiers in Genetics, 4, 56. doi: 10.3389/fgene.2013.00056

More publications...